Pediatric Pulmonology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 16, 2024
Abstract
Introduction
Asthma
imposes
a
crucial
economic
burden
on
health
systems,
especially
with
the
incorporation
of
new
drugs.
Recently,
mepolizumab
has
been
approved
to
prevent
exacerbations
in
patients
eosinophilic
asthma.
This
study
explores
economically
justifiable
price
for
preventing
children
severe
Materials
and
Methods
A
model
was
developed
using
microsimulation
estimate
quality‐adjusted
costs
life
years
two
interventions:
versus
not
applying
standard
treatment
without
mepolizumab.
analysis
made
during
time
horizon
50
from
third‐payer
perspective.
Results
Mepolizumab
cost‐effective
WTP
U$
19,992
per
QALY,
but
at
4828,
5128
QALY.
The
cost
Colombia
is
between
$33
$350
dose,
respectively.
At
current
Mepolizumab,
780
only
higher
than
10,300
QALY
will
be
best
alternative
no
Conclusion
Our
shows
that
4828
5180
result
should
encourage
more
studies
region
optimize
decision‐making
processes
when
incorporating
this
drug
into
plans
each
country.
Current Opinion in Pediatrics,
Journal Year:
2024,
Volume and Issue:
36(3), P. 304 - 309
Published: Feb. 23, 2024
Precision
medicine
in
pediatric
asthma
involves
identification
of
phenotypes,
genetic
markers,
biomarkers,
and
biologics
that
target
specific
pathways.
This
review
includes
a
discussion
the
efficacy
currently
approved
for
most
recent
advances
biomarker/phenotype
associations
affect
care.
Children,
Journal Year:
2024,
Volume and Issue:
11(7), P. 843 - 843
Published: July 11, 2024
Severe
asthma
(SA)
is
still
a
demanding
challenge
in
clinical
practice.
Type
2
inflammation
the
most
common
phenotype
children
and
adolescents
with
SA.
As
result,
anti-inflammatory
drugs,
mainly
corticosteroids
(CSs),
represent
first
choice
to
reduce
type
inflammation.
However,
SA
patients
may
require
high
inhaled
oral
CS
doses
achieve
maintain
control.
Some
patients,
despite
highest
dosages,
can
even
display
uncontrolled
asthma.
Therefore,
biological
era
constituted
breakthrough
managing
this
condition.
Dupilumab
monoclonal
antibody
directed
against
IL-4
receptor
α-subunit
(IL-4Rα),
antagonizing
both
IL-13,
has
been
approved
for
pediatric
severe
This
review
presents
discusses
recent
published
studies
on
dupilumab
There
convincing
evidence
that
safe
effective
option
as
it
exacerbations,
use,
improve
lung
function,
control,
quality
of
life,
also
caregivers.
thorough
diagnostic
pathway
mandatory,
concerning
phenotyping.
In
fact,
ideal
eligible
candidate
child
or
adolescent
allergic
phenotype.
Pediatric Pulmonology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 16, 2024
Abstract
Introduction
Asthma
imposes
a
crucial
economic
burden
on
health
systems,
especially
with
the
incorporation
of
new
drugs.
Recently,
mepolizumab
has
been
approved
to
prevent
exacerbations
in
patients
eosinophilic
asthma.
This
study
explores
economically
justifiable
price
for
preventing
children
severe
Materials
and
Methods
A
model
was
developed
using
microsimulation
estimate
quality‐adjusted
costs
life
years
two
interventions:
versus
not
applying
standard
treatment
without
mepolizumab.
analysis
made
during
time
horizon
50
from
third‐payer
perspective.
Results
Mepolizumab
cost‐effective
WTP
U$
19,992
per
QALY,
but
at
4828,
5128
QALY.
The
cost
Colombia
is
between
$33
$350
dose,
respectively.
At
current
Mepolizumab,
780
only
higher
than
10,300
QALY
will
be
best
alternative
no
Conclusion
Our
shows
that
4828
5180
result
should
encourage
more
studies
region
optimize
decision‐making
processes
when
incorporating
this
drug
into
plans
each
country.
